Ascendis Pharma A-S

Ascendis Pharma boosts growth with analyst‑backed buy/overweight ratings, a $120 M share‑repurchase, and strong FY25‑26 revenue outlooks.

Ascendis Pharma Q3 2025 outlook: tighter losses, $213 m revenue, and strong TransCon PTH clinical gains amid a $1.15 bn hypoparathyroidism market.

Ascendis Pharma A/S, a Danish biotechnology company, is a leader in the industry with a diverse portfolio of pharmaceutical products and a strong market presence, driven by its strategic focus on developing treatments for complex health conditions.